News

News Archive

August 2010
Cancer research in Owensboro gets $4.5 million

The University of Louisville has received a $3.15 million grant from the Helmsley Charitable Trust to support the U of L James Graham Brown Cancer Center and cancer research taking place in Owensboro. The grant will be matched with state "Bucks for Brains" funding to bring more than $4.5 million to the Owensboro Cancer Research Program.

March 2010
KBP to accelerate vaccine-grade protein production

The Defense Advanced Research Projects Agency (DARPA) has announced that KBP is being awarded an agreement for developing a proof-of-concept platform capable of delivering vaccine grade recombinant protein, an essential component of future vaccines.

September 2009
KBP to develop process for anti-rabies antibody

KBP has signed an agreement with the South African-based Council for Scientific and Industrial Research (CSIR) to develop a commercially efficient process for RabiVir,TM—CSIR’s award-winning anti-rabies antibody developed in a start up venture with GreenPharmTM.

August 2009
Tobacco plants yield vaccine for cruise ship virus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

March 30, 2009
Preventative drug for HIV manufactured in plants ready to begin clinical development

A University of Louisville faculty member at the Owensboro Cancer Research Program (OCRP) will publish research supporting the use of transgenic plants in HIV prevention. The study indicates that growing large quantities of the protein griffithsin in Nicotiana benthamiana – a close relative of tobacco – offers an affordable, preventative measure for HIV.

September 2008
Bayer broadens its manufacturing basis for biopharmaceuticals in tobacco plants

Bayer Innovation GmbH and Kentucky Bioprocessing are collaborating to develop a facility at KBP’s Owensboro plant for the production service of biopharmaceuticals. Based on Bayer’s proprietary magnICON® technology, plant made pharmaceutical proteins and other high-value products will be produced in tobacco plants on commercial scale.

September 2008
New plant biotechnology company founded to focus on biomaterials and biopharmaceuticals

NOMAD Bioscience GmbH, Munich, Germany is a private biotechnology company developing plant-made biomaterials and biopharmaceuticals that address critical unmet needs.

September 2008
Nomad Bioscience announces broad license agreement

Nomad Bioscience GmbH announces that it entered into a broad licensing agreement with Bayer Innovation GmbH and Icon Genetics group. It provides Nomad access to Icon’s proprietary technology platforms, including its transient expression technology magnICON®, for manufacturing biomaterials and selected biosimilar pharmaceutical proteins in green plants.

August 2008
KBP Awarded Patent for Development of Parvovirus Vaccine

The United States Patent and Trademark Office has awarded a patent to Owensboro based Kentucky BioProcessing, LLC, enabling production of a parvovirus vaccine with potential for both feline and canine applications. Parvovirus is a sometimes fatal infectious disease affecting many small animals including domesticated dogs and cats.

July 2008
KBP’s Geneware product to be used in HPV vaccine development

The University of Louisville’s James Graham Brown Cancer Center has licensed technology for a second-generation vaccine against the human papillomavirus (HPV) to Advanced Cancer Therapeutics (ACT), a Louisville-based private company. In order to bring the vaccine to market quickly, ACT has also licensed rights to GENEWARE®, a technology owned by Owensboro-based Kentucky BioProcessing, LLC (KBP).

June 2008
KBP Acquires Plant Based Gene Expression Technology

As part of a continued commitment to maintaining its position as a world leader in the development of the plant-made pharmaceutical industry, Kentucky BioProcessing, LLC (KBP) recently completed acquisition of the GENEWARE® intellectual property platform, designed and created to enable the expression of genes and the proteins which they encode in plants.

September 2007
Mapp to expand operations to KBP’s campus

As part of its focus on development of a commercial scale production platform for its products, Mapp Biopharmaceutical, Inc. (Mapp) today announced that the company will expand operations to the Kentucky Bioprocessing (KBP) campus in Owensboro, Kentucky.

August 2007
Mapp and KBP expanding

Mapp Biopharmaceutical, Inc. (Mapp) and Kentucky Bioprocessing (KBP) are expanding their ongoing collaboration aimed at developing, refining and producing low-cost pharmaceutical products for large, cost sensitive markets in global health.

July 2007
Partnership to develop low-cost pharmaceutical products

The Biodesign Institute at Arizona State University, Mapp Biopharmaceutical and Kentucky Bioprocessing (KBP) will collaborate on developing, refining and producing low-cost pharmaceutical products for large, cost-sensitive markets in global health.